Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 504

1.

Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study.

Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, Ellis PM.

EBioMedicine. 2016 Mar;5:125-34.

PMID:
27532076
2.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 Apr;33(4):1003-17. doi: 10.1007/s11095-015-1846-4. Erratum in: Pharm Res. 2016 May;33(5):1305-6.

PMID:
26718955
3.
4.

Determination of Drugs in Plasma Samples by High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Schizophrenic Patients.

Domingues DS, Pinto MA, de Souza ID, Hallak JE, Crippa JA, Queiroz ME.

J Anal Toxicol. 2016 Jan-Feb;40(1):28-36. doi: 10.1093/jat/bkv107.

PMID:
26333987
5.

Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).

Diana MC, Santoro ML, Xavier G, Santos CM, Spindola LN, Moretti PN, Ota VK, Bressan RA, Abilio VC, Belangero SI.

Psychiatry Res. 2015 Oct 30;229(3):690-4. doi: 10.1016/j.psychres.2015.08.021.

PMID:
26296755
6.

AMIGO-Kv2.1 Potassium Channel Complex Is Associated With Schizophrenia-Related Phenotypes.

Peltola MA, Kuja-Panula J, Liuhanen J, Võikar V, Piepponen P, Hiekkalinna T, Taira T, Lauri SE, Suvisaari J, Kulesskaya N, Paunio T, Rauvala H.

Schizophr Bull. 2016 Jan;42(1):191-201. doi: 10.1093/schbul/sbv105.

7.

Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia.

Kippe JM, Mueller TM, Haroutunian V, Meador-Woodruff JH.

Schizophr Res. 2015 Aug;166(1-3):219-24. doi: 10.1016/j.schres.2015.06.002.

8.

mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.

Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJ, Niswender K, Galli A.

J Neurosci. 2015 Jun 10;35(23):8843-54. doi: 10.1523/JNEUROSCI.0887-15.2015.

9.

Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia.

O'Donovan SM, Hasselfeld K, Bauer D, Simmons M, Roussos P, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE.

Transl Psychiatry. 2015 Jun 9;5:e579. doi: 10.1038/tp.2015.74.

10.

Hybrid silica monolith for microextraction by packed sorbent to determine drugs from plasma samples by liquid chromatography-tandem mass spectrometry.

de Souza ID, Domingues DS, Queiroz ME.

Talanta. 2015 Aug 1;140:166-75. doi: 10.1016/j.talanta.2015.03.032.

PMID:
26048838
11.
12.

Catha edulis chewing effects on treatment of paranoid schizophrenic patients.

Kotb El-Sayed MI, Amin HK.

Neuropsychiatr Dis Treat. 2015 Apr 15;11:1067-76. doi: 10.2147/NDT.S81011.

13.

[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].

Potanin SS, Burminsky DS, Morozova MA, Platova AI, Baymeeva NV, Miroshnichenko II.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(11):40-6. Russian.

PMID:
26978050
14.

In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.

Suzuki K, Harada A, Shiraishi E, Kimura H.

J Pharmacol Exp Ther. 2015 Mar;352(3):471-9. doi: 10.1124/jpet.114.218552.

15.

Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.

Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J, Chaki S, Hikichi H.

Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046.

PMID:
25300471
16.

Nerve growth factor and its receptor in schizophrenia.

Zakharyan R, Atshemyan S, Gevorgyan A, Boyajyan A.

BBA Clin. 2014 May 20;1:24-9. doi: 10.1016/j.bbacli.2014.05.001.

17.

A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes.

Meyer JM.

CNS Spectr. 2014 Oct;19(5):432-8. doi: 10.1017/S1092852914000236. Review.

PMID:
24865765
18.

Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.

Nakamura A, Mihara K, Nemoto K, Nagai G, Kagawa S, Suzuki T, Kondo T.

Ther Drug Monit. 2014 Dec;36(6):815-8. doi: 10.1097/FTD.0000000000000082.

PMID:
24739668
19.

Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.

Pilla Reddy V, Kozielska M, Johnson M, Mafirakureva N, Vermeulen A, Liu J, de Greef R, Rujescu D, Groothuis GM, Danhof M, Proost JH.

J Clin Psychopharmacol. 2013 Dec;33(6):731-9. doi: 10.1097/JCP.0b013e3182a4ee2c.

PMID:
24113674
20.

Deficits in latent inhibition induced by estradiol replacement are ameliorated by haloperidol treatment.

Almey A, Hafez NM, Hantson A, Brake WG.

Front Behav Neurosci. 2013 Oct 1;7:136. doi: 10.3389/fnbeh.2013.00136.

Items per page

Supplemental Content

Loading ...
Support Center